Fight Colorectal Cancer shared a post on LinkedIn:
“Big news for MSS colorectal cancer!
At ESMO GI 2025, our Fight CRC Research Advocate, Elsa Lankford, was on the ground learning about a new drug combo – botensilimab + balstilimab—that’s giving hope to patients with few options.
– Tumors shrank in some patients
– Many saw their cancer stop growing
– Some responses lasted well over a year
A Phase 3 trial is on the way, bringing this treatment one step closer to becoming an option outside of trials.
Elsa breaks down the results and what’s next in our blog: What We Learned at ESMO GI 2025 About Botensilimab + Balstilimab.
Right now, this combo is only available through clinical trials—see if one could be a match for you or someone you love.
Want more updates like this in your inbox? Subscribe to our More Time, More Options CRC clinical trials newsletter.”
More posts featuring Fight Colorectal Cancer on OncoDaily.